Meyer Handelman Co. Has $21.45 Million Position in Bristol Myers Squibb Company $BMY

Meyer Handelman Co. trimmed its stake in Bristol Myers Squibb Company (NYSE:BMY) by 9.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 475,518 shares of the biopharmaceutical company’s stock after selling 52,438 shares during the quarter. Meyer Handelman Co.’s holdings in Bristol Myers Squibb were worth $21,446,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Trifecta Capital Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $25,000. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb in the second quarter worth approximately $25,000. CBIZ Investment Advisory Services LLC grew its stake in Bristol Myers Squibb by 66.0% in the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 231 shares during the period. GKV Capital Management Co. Inc. bought a new stake in shares of Bristol Myers Squibb during the first quarter valued at approximately $36,000. Finally, Harbor Capital Advisors Inc. raised its position in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of recent research reports. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Citigroup reduced their price objective on shares of Bristol Myers Squibb from $48.00 to $45.00 and set a “neutral” rating for the company in a report on Monday, November 17th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Guggenheim reiterated a “buy” rating on shares of Bristol Myers Squibb in a research note on Tuesday. Finally, Morgan Stanley reissued an “underweight” rating and issued a $37.00 price objective (up from $36.00) on shares of Bristol Myers Squibb in a research note on Friday, December 12th. Six investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $54.62.

Bristol Myers Squibb Stock Down 0.1%

Bristol Myers Squibb stock opened at $54.65 on Friday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. The firm’s 50-day simple moving average is $48.83 and its 200 day simple moving average is $47.37. The stock has a market cap of $111.26 billion, a PE ratio of 18.46, a price-to-earnings-growth ratio of 8.37 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The firm had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. During the same quarter last year, the business posted $1.80 EPS. The company’s revenue for the quarter was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be paid a $0.63 dividend. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.6%. Bristol Myers Squibb’s dividend payout ratio is currently 83.78%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.